semaglutide novo nordisk patent Ozempic, Wegovy and Rybelsus: The patents behind Nordisk's weight-loss drugs Patent expires next year: Novo

In this case, although GLP-1 users had about twice the relative risk of ischemic optic neuropathy compared to other drugs, the absolute increase was only around 3 to 4 extra cases per 10,000 people over 18 monthsmeaning the overall chance remains very small

they take your money and deliver far less than promised

Reapply every two hours, or more often if you are sweating or swimming

Informed Sport AccreditedTested for banned substances, making it a trusted choice for athletes and sports professionals seeking safe nutrition

but lower doses led to more modest weight loss:Lower doses had a more favourable side effect profile, too:This triple agonism aims to relieve some of the side effects of GLP1s (nausea, muscle loss), and increase weight loss (so the dose can be lowered)Sources: New obesity drugs - nature.com/articles/d4158 Triple agonist Retatrutide phase 2 trial - nejm.org/doi/full/10.10 full article: openread.academy/en/paper/readi Breakdown of the article: The article discusses the development of new obesity drugs that aim to provide greater and healthier weight loss